An interventional study of Menthol inhalation and Strawberry scent in Dyspnea and Chronic Obstructive Pulmonary Disease, sponsored by KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-19.
Sponsored by KU Leuven · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Dyspnea with a site in Belgium — 3 open to participants now, 3 under way, none of them phase 3. Dyspnea · Belgium.
Among the 19 studies in Dyspnea with a site in Belgium, this one is the 7th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2023, is one of 5 with no phase, and was the 16th registered.
895 studies on the registry are indexed under Dyspnea; 189 are open to participants now.
Browse Dyspnea studies →3 of the 19 studies in Dyspnea with a site in Belgium are open now. Recruiting first, the newest first:
Ziekenhuis Oost-Limburg · Sites in Belgium
Healthy volunteers
Pfizer · Sites in Belgium, United States, Argentina and 12 more countries
Ages 18–75
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 125 Dyspnea studies recruiting now, 68 (54%) set no upper age limit and 41 (33%) stop at 75 or younger; 18 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 4
First in 2005; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 50 across 588 interventional studies indexed under Dyspnea.
Median enrollment 120 across the 13 interventional studies, 1,387 across the 6 observational. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 19 have an industry lead sponsor. The 10 most frequent:
KU Leuven is the lead sponsor of 373 studies on the registry; 65 are open to participants now.
KU Leuven has 4 studies filed under Dyspnea — fewer than ten, so there is no comparison to draw.
1 of the studies in Dyspnea with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06977581PfizerA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | 2027-03-08 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Dyspnea with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Menthol inhalation (MI) is a novel and promising treatment option for acute relief of dyspnea, however, the underlying ventilatory and/or neural related mechanisms for this relief in symptoms remain unknown. The overall aim of this research project is to systematically examine the mechanisms of dyspnea relief from MI in healthy individuals and those with COPD.
The project is structured in 5 work packages (WP), each including a different sample of healthy volunteers (WP1, 2) or patients with COPD (WP3, 4, 5), respectively with a 1:1 female/male ratio in each WP. Each WP will be single-blind, placebo-controlled cross-over trial to investigate the effects of MI compared to placebo in healthy volunteers during resistive loaded breathing (WP1), in healthy volunteers during cycling exercise (WP2), in people with COPD who have dyspnea at rest (WP3), and in people with COPD during cycling exercise (WP4, 5).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Menthol inhalation during resistive loaded breathing trials in healthy participants.
Other: Menthol inhalation
Strawberry scent during resistive loaded breathing trials in healthy participants.
Other: Strawberry scent
Menthol inhalation during cycle exercise in healthy participants.
Other: Menthol inhalation
Strawberry scent during cycle exercise in healthy participants.
Other: Strawberry scent
Menthol inhalation during resting breathing in dyspneic COPD participants.
Other: Menthol inhalation
Strawberry scent during resting breathing in dyspneic COPD participants.
Other: Strawberry scent
Resting breathing in dyspneic COPD participants.
Menthol inhalation during cycle exercise in COPD participants.
Other: Menthol inhalation
Strawberry scent during cycle exercise in COPD participants.
Other: Strawberry scent
Menthol inhalation and facial airflow during cycle exercise in COPD participants
Other: Menthol inhalation and facial airflow
Strawberry inhalation and airflow to leg during cycle exercise in COPD participants
Other: Strawberry scent and airflow to leg
Menthol inhalation and airflow to leg during cycle exercise in COPD patients
Other: Menthol inhalation and airflow to leg
Strawberry inhalation and facial airflow during cycle exercise in COPD patients
Other: Strawberry inhalation and facial airflow
300 milligrams of L-menthol will be deposited on to a cellulose swab and secured inside the lower portion of a sealed facemask.
600 microliters of 100% natural strawberry flavoring will be deposited onto on to a cellulose swab and secured inside the lower portion of a sealed facemask.
Menthol will be administered using a noseplug and facial airflow will be applied with a tabletop fan.
Strawberry will be administered using a noseplug and airflow to the leg will be applied with a tabletop fan.
Menthol will be administered using a noseplug and airflow to the leg will be applied with a tabletop fan.
Strawberry will be administered using a noseplug and facial airflow will be applied with a tabletop fan.
Difference in respiratory-related evoked potentials (RREP) with menthol vs. strawberry.
RREPs will be measured using an electroencephalogram (EEG) sensor cap connected to a high-density 129 channel EEG system during breathing trials and exercise tests. Inspiration will briefly be interrupted for 150 milliseconds every two to six breaths by activation of the occluder, which induces the RREP in the EEG signal.
Time frame: 1 week
Difference in diaphragmatic electromyography with menthol vs. strawberry.
Diaphragmatic electromyography will be measured using a multi-pair electrode catheter during breathing trials and exercise tests. and used as an index of neural respiratory drive.
Time frame: 1 week
Difference in dyspnea with menthol vs. strawberry (+ facial airflow or airflow to leg in WP5).
Dyspnea ratings will be measured using the Borg 0-10 category ratio scale and will be assessed at the end of each 5-minute breathing trial (WP1 and 3), and at baseline, every minute during (WP4,5) or halfway through the test (WP2), and at peak of each cycle exercise test. 0 represents no dyspnea at all and then 10 the most maximal dyspnea ever experienced or could be imagined experiencing.
Time frame: 1 week
Difference in the rate of perceived inspiratory airflow.
Participants will be asked: "In which of the four conditions did your airflow feel easier when breathing in?" at the end of each study visit.
Time frame: 1 week
Perception of a cooling sensation.
Participants will be asked: "In which of the four conditions did you feel a fresh or cooling sensation when breathing in?" at the end of each study visit.
Time frame: 1 week
Difference in activation of extra-diaphragmatic inspiratory muscles with menthol vs. strawberry.
Activation of extra-diaphragmatic inspiratory muscles will be measured using bipolar surface electrodes during breathing trials (WP3) and exercise testing (WP4).
Time frame: 1 week
Difference in the cardiorespiratory responses to exercise with menthol vs. strawberry.
Cardiorespiratory responses to exercise will be measured on a breath-by-breath basis using a commercially available cardiopulmonary testing system during exercise testing.
Time frame: 1 week
Difference in respiratory pressures with menthol vs. strawberry.
Respiratory pressures will be measured using esophageal and gastric balloons during breathing trials and exercise testing.
Time frame: 1 week
Difference in leg discomfort ratings with menthol vs. strawberry (+facial airflow or airflow to leg in WP5).
Leg discomfort will be measured using the Borg 0-10 category ratio scale at baseline, every minute during (WP4, 5) or halfway through the test (WP2), and at peak of each cycle exercise test. 0 represents no leg discomfort at all and then 10 the most maximal leg discomfort ever experienced or could be imagined experiencing.
Time frame: 1 week
Difference in exercise endurance time with menthol vs. strawberry (+ facial airflow or airflow to leg in WP5).
Exercise endurance time will be measured during submaximal constant load cycle exercise testing (WP4, 5).
Time frame: 1 week
Difference in the reasons for stopping exercise with menthol vs. strawberry (+facial airflow or airflow to leg in WP5).
Participants will be asked to give their reasons for stopping (e.g., "breathing discomfort," "leg discomfort," "a combination of breathing and leg discomfort," or "other") and attributing a percentage to each of breathing discomfort and leg discomfort to total 100 (WP 2, 4 and 5).
Time frame: 1 week
Difference in ratings of affective state on the dimensions of valence and arousal with menthol vs. strawberry (+ facial airflow or airflow to leg in WP5).
Dimensions of valence and arousal will be measured using the 9-point Self-Assessment Manikin scale for valence (1 -"unpleasant" to 9 -"pleasant") and arousal (1-"calm" to 9-"aroused") at the end of each breathing trial (WP 1 and 3) and at peak exercise (WP 2, 4 and 5).
Time frame: 1 week
Difference in the Neural Drive to Breathe (P0.1)
The neural drive to breathe will be measured using airway occlusion pressure (P0.1), evoked by inspiratory occlusions delivered during the test (WP1 and 2).
Time frame: 1 week
Plan to share: No
Started Jan 2023 (actual). Primary completion is estimated for Oct 2028, 69 months after the start.
Of 268 non-industry interventional studies with no phase under Dyspnea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 69 months is above that.
Counting every sponsor, half of 284 studies reached it within 13 months; a quarter within 6 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.